E-cadherin Positive: What It Means for Cancer Diagnosis

An E-cadherin positive result on a pathology report means the tumor cells are still producing E-cadherin, a protein that acts like molecular glue between cells. In most solid cancers, retaining this protein is considered a favorable sign, because its loss is linked to more aggressive behavior and a greater tendency for cells to spread. The most common reason pathologists order the stain, though, is not to judge prognosis but to answer a more immediate question about what kind of tumor they are looking at, especially in breast cancer.

What E-cadherin Does in Normal Tissue

E-cadherin sits on the outer surface of epithelial cells, the cells that line organs, ducts, and glands throughout the body. It depends on calcium to work: neighboring cells extend E-cadherin molecules that lock together, forming strong junctions that hold tissue architecture in place.¹ Without functioning E-cadherin, sheets of epithelial cells lose their organized structure, which is one reason the protein has long been classified as a tumor suppressor.² When cancer cells stop making E-cadherin, they loosen their grip on their neighbors and become better able to invade surrounding tissue. That biological fact underpins virtually every clinical use of E-cadherin staining.

The Main Diagnostic Use in Breast Cancer

If you see E-cadherin on a pathology report for a breast biopsy, the stain was almost certainly ordered to help distinguish between two major types of breast cancer: invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC). The distinction matters because the two types behave differently, respond to different treatment strategies, and can look ambiguous under the microscope when the pathologist is working from a small core biopsy.

The pattern is straightforward in most cases. Ductal carcinomas retain strong, continuous E-cadherin staining along the cell membranes, while lobular carcinomas characteristically lose it. One study found that all cases of invasive ductal carcinoma showed moderate to strong membranous E-cadherin staining, while only a single case of invasive lobular carcinoma did the same.³ So when a pathologist reports E-cadherin positive in a breast lesion, they are generally supporting a ductal classification.

The same logic applies to pre-invasive disease. Ductal carcinoma in situ (DCIS) retains E-cadherin, whereas lobular carcinoma in situ (LCIS) does not. A cocktail stain combining E-cadherin with another protein called p120 catenin can make this distinction even clearer on a single slide: DCIS shows membranous staining for both markers, while LCIS loses the E-cadherin membrane staining and instead shows p120 catenin relocated into the cell’s interior.⁴ That cocktail approach is particularly useful when the pathologist is working with a small biopsy that has only a tiny focus of abnormal cells.

When a Positive Result Can Mislead

The ductal-versus-lobular rule works well as a general principle, but it is not absolute. Some lobular carcinomas stain positive for E-cadherin, and misreading that result can lead a pathologist to incorrectly reclassify a lobular tumor as ductal. A study examining this problem found that four cases of invasive lobular carcinoma were E-cadherin positive, but each showed aberrant staining patterns rather than the clean, unbroken membrane signal seen in true ductal tumors.⁵ The authors cautioned that positive E-cadherin staining alone should not rule out a lobular diagnosis.

Pathologists have learned to look not just at whether staining is present, but at how it looks. Normal ductal staining is strong, continuous, and wraps completely around each cell’s membrane. Aberrant staining in lobular tumors tends to be weaker, fragmented, or dot-like. One classification system grades the pattern into categories: negative (no staining at all), strong and diffuse (the healthy ductal pattern), heterogeneous (patchy with some areas missing), and reduced or weak (faint, granular, discontinuous).⁶ A 2024 study further confirmed that even among lobular carcinomas showing diffuse E-cadherin staining, the intensity scores were lower than normal and most displayed an abnormal, discontinuous membrane pattern.⁷

The practical takeaway: if you see “E-cadherin positive” on a breast pathology report, the context matters. Strong, uniform membrane staining supports a ductal diagnosis confidently. Weak, patchy, or cytoplasmic positivity is a red flag that the tumor might still be lobular despite the positive result. Good pathology reports will describe the staining pattern, not just report it as positive or negative.

Prognostic Meaning Across Different Cancers

Beyond classification, E-cadherin status carries prognostic information in several cancer types, though the direction of that information is not always the same.

In colorectal cancer, the data are consistent and strong. A meta-analysis found that patients whose tumors had low E-cadherin expression had roughly double the risk of dying compared to those with high expression, with a hazard ratio of about 2.09 for overall survival and 2.03 for disease-free survival.⁸ A separate analysis confirmed that E-cadherin was the only adhesion marker with independent prognostic value when tested alongside other candidates in multivariable models.⁹ In plain terms, colorectal tumors that are E-cadherin positive tend to be less aggressive.

Ovarian cancer follows a similar pattern. A pooled analysis showed that negative E-cadherin expression predicted shorter overall survival, with a hazard ratio of about 1.90. Loss of E-cadherin also correlated with more advanced stage, higher tumor grade, and greater likelihood of metastasis and recurrence.¹⁰ In ovarian clear cell carcinoma specifically, patients whose tumors expressed E-cadherin in more than ten percent of cells had significantly better five-year survival than those whose tumors did not.¹¹

Lung cancer introduces a wrinkle. In one study of advanced lung adenocarcinoma with EGFR mutations, high E-cadherin expression was actually associated with worse overall survival.¹² This seemingly contradictory finding may relate to the fact that E-cadherin-positive tumor clusters can still metastasize collectively, traveling as cohesive groups rather than as individual cells. The biology is more nuanced than a simple “positive equals good” formula, and the tumor type and molecular context shape what E-cadherin positivity actually means for a given patient.

E-cadherin Re-Expression at Metastatic Sites

One of the more counterintuitive findings in E-cadherin research is that tumors can switch the protein off to spread and then switch it back on once they reach a distant organ. This is part of a broader phenomenon: cancer cells may lose their epithelial character to invade and travel through the bloodstream, then revert to an epithelial state once they arrive at a new site and need to settle down and grow.

In breast cancer, a study comparing primary tumors to their liver, lung, and brain metastases found that about 62 percent of cases showed increased E-cadherin expression in the metastases compared to the original tumor.¹³ A separate study found that all metastatic deposits from invasive ductal carcinomas expressed E-cadherin at levels equal to or stronger than the primary tumor, and proposed that re-expression helps circulating tumor cells stick together and form a viable colony at the new site.¹⁴

Experiments using metastatic breast cancer cell lines confirmed this in laboratory animals: cancer cells injected into mice showed a greater percentage of E-cadherin-positive cells at the secondary metastatic site than at the primary tumor location.¹⁵ The mechanism appears to involve changes in how the E-cadherin gene is chemically silenced: the surrounding tissue at the metastatic site can prompt the gene to become active again through passive loss of the methylation that was keeping it quiet.¹³

This has a practical implication for interpreting pathology reports. If a biopsy from a metastatic deposit comes back E-cadherin positive, that does not necessarily mean the original tumor was also positive, and it does not guarantee a less aggressive disease course. The positivity in a metastasis may reflect this re-expression phenomenon rather than the tumor’s inherent biology.

E-cadherin as a Predictor of Treatment Response

E-cadherin status is beginning to factor into predictions about which therapies might work best. In colorectal cancer, low E-cadherin expression has been linked to poor response to EGFR-targeted therapies like cetuximab. When researchers experimentally knocked down E-cadherin in colorectal cancer cells that were responding to cetuximab, those cells stopped responding.¹⁶ The suggestion is that E-cadherin positivity may help identify patients more likely to benefit from these drugs.

A similar relationship exists in lung cancer. Laboratory work found a significant correlation between E-cadherin expression and sensitivity to gefitinib, an EGFR inhibitor. When researchers forced a gefitinib-resistant lung cancer cell line to produce E-cadherin, the cells became more sensitive to the drug.¹⁷ In ovarian clear cell carcinoma, E-cadherin positivity predicted better outcomes specifically among women receiving paclitaxel-based chemotherapy, and both E-cadherin expression and paclitaxel use emerged as independent favorable factors for survival.¹¹

None of these findings have yet translated into formal treatment guidelines that say “test E-cadherin before prescribing.” The evidence is promising but still in the realm of research that informs clinical thinking rather than dictating specific drug choices.

CDH1 Mutations and Hereditary Cancer Syndromes

The gene that codes for E-cadherin is called CDH1, and inherited mutations in this gene are linked to two specific cancer syndromes. The best known is hereditary diffuse gastric cancer, a condition that carries a very high lifetime risk of stomach cancer. CDH1 germline mutations also predispose carriers to lobular breast carcinoma.¹⁸

For people who carry a pathogenic CDH1 mutation, the recommended course of action can be dramatic. Prophylactic total gastrectomy (removing the entire stomach before cancer develops) is considered a standard recommendation because diffuse gastric cancer is difficult to detect early with endoscopy and has a poor prognosis when caught late.¹⁹ Guidelines also recommend enhanced breast cancer surveillance for female carriers.

The connection between these germline mutations and E-cadherin staining on a pathology report is indirect but worth understanding. A tumor that has lost E-cadherin expression through a somatic (non-inherited) mutation is not evidence that the patient carries a germline CDH1 mutation. Conversely, someone with a germline CDH1 mutation will not necessarily show E-cadherin loss in every tissue biopsy. Genetic counseling and dedicated CDH1 genetic testing are separate processes from the immunohistochemistry stain on a tumor biopsy.

Soluble E-cadherin in Blood Tests

Researchers have explored whether a fragment of E-cadherin that is shed into the bloodstream, called soluble E-cadherin, could serve as a cancer biomarker measurable from a simple blood draw rather than a tissue biopsy. In breast cancer, serum soluble E-cadherin levels were significantly elevated in patients compared to healthy controls, and a receiver operating characteristic analysis showed strong discriminating ability with a sensitivity around 79 percent and specificity near 89 percent at an optimal cutoff. Levels also correlated with tumor stage, grade, and lymph node spread.²⁰

In colorectal cancer, soluble E-cadherin outperformed the traditional blood markers CEA, CA19-9, and CA125 in distinguishing patients from healthy individuals, and combining soluble E-cadherin with CEA pushed sensitivity above 82 percent.²¹ These blood-based measurements remain investigational and are not part of routine clinical practice yet, but they represent a potential future where E-cadherin testing does not require a tissue sample at all.

Technical Factors That Can Affect the Result

E-cadherin staining is not immune to laboratory artifacts. Because E-cadherin is a membrane-bound protein, its detection depends on well-preserved tissue. A study examining the effect of delayed formalin fixation, the process of preserving tissue after it is removed from the body, found that E-cadherin staining was among the markers most affected by delay. Membrane markers like E-cadherin showed significant alteration when fixation was not prompt, potentially converting a truly positive result into a falsely weak or negative one.²²

Different antibody clones used in the staining process can also produce subtly different results. One breast cancer study compared two widely used E-cadherin antibody clones and found that one was more reproducible and correlated better with the tumor’s actual morphology.²³ This means that a borderline E-cadherin result from one laboratory might not be exactly reproduced at another, particularly for cases that fall into the gray zone between clearly positive and clearly negative. If a pathology report describes E-cadherin staining as equivocal or reduced rather than straightforwardly positive or negative, these technical variables are part of the reason.

E-cadherin in Ovarian Cancer and Mesothelioma

Ovarian cancer adds an unusual twist to the E-cadherin story. Normal ovarian surface cells do not actually express E-cadherin, but the protein appears when those cells become trapped in inclusion cysts beneath the ovarian surface. Benign and borderline ovarian tumors uniformly express E-cadherin, and so do malignant ovarian cancers at all stages. E-cadherin was not found to be downregulated even in advanced-stage disease and was present in metastases.²⁴ This means that in ovarian cancer, E-cadherin positivity does not separate benign from malignant the way it helps separate ductal from lobular breast cancer. Instead, E-cadherin appears to play a role in the earliest steps of ovarian cancer development, and its persistent expression complicates any attempt to use it as a simple marker of tumor aggression in this organ.

Mesothelioma, a cancer arising from the mesothelial lining of the chest or abdomen, also shows E-cadherin expression in a majority of cases. Since normal mesothelial cells express very little E-cadherin, finding it upregulated in mesothelioma tumors is itself notable, though the biological significance remains unclear. The more heterogeneous and less predictable cadherin expression in mesothelioma compared to carcinomas means that E-cadherin staining in this disease has a different diagnostic value than it does in breast or colorectal cancer.

Collective Invasion and Why Positive Does Not Always Mean Harmless

A common misconception is that because E-cadherin loss promotes invasion, E-cadherin positivity must therefore prevent it. The reality is more complicated. Certain aggressive tumors invade as cohesive clusters of cells that maintain E-cadherin-mediated connections. Studies of mammary carcinoma cells have shown that E-cadherin plays a dual role: it restrains individual cell migration but actually facilitates collective invasion, where groups of connected cells push into surrounding tissue together. In mouse experiments, these E-cadherin-positive tumor cell clusters formed interconnected tethers and went on to produce metastatic nodules in the lungs.²⁵

This dual role helps explain why E-cadherin positivity does not guarantee a good prognosis in every cancer type, and why the protein’s significance varies by context. In colorectal cancer, where individual cell invasion predominates, keeping E-cadherin is generally protective. In certain lung adenocarcinomas or inflammatory breast cancers where collective invasion matters more, E-cadherin positivity may have a different or even adverse meaning. The stain result is one piece of a larger puzzle that includes tumor type, grade, stage, molecular subtype, and the specific pattern of E-cadherin expression on the slide.